Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Antibiotic-Induced Dysbiosis Predicts Mortality in an Animal Model of Clostridium difficile Infection.

Burdet C, Sayah-Jeanne S, Nguyen TT, Hugon P, Sablier-Gallis F, Saint-Lu N, Corbel T, Ferreira S, Pulse M, Weiss W, Andremont A, Mentré F, de Gunzburg J.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00925-18. doi: 10.1128/AAC.00925-18. Print 2018 Oct.

2.

Protection of Hamsters from Mortality by Reducing Fecal Moxifloxacin Concentration with DAV131A in a Model of Moxifloxacin-Induced Clostridium difficile Colitis.

Burdet C, Sayah-Jeanne S, Nguyen TT, Miossec C, Saint-Lu N, Pulse M, Weiss W, Andremont A, Mentré F, de Gunzburg J.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00543-17. doi: 10.1128/AAC.00543-17. Print 2017 Oct.

3.

An in vitro culture model to study the dynamics of colonic microbiota in Syrian golden hamsters and their susceptibility to infection with Clostridium difficile.

Miezeiewski M, Schnaufer T, Muravsky M, Wang S, Caro-Aguilar I, Secore S, Thiriot DS, Hsu C, Rogers I, DeSantis T, Kuczynski J, Probst AJ, Chehoud C, Steger R, Warrington J, Bodmer JL, Heinrichs JH.

ISME J. 2015 Feb;9(2):321-32. doi: 10.1038/ismej.2014.127. Epub 2014 Jul 18.

4.

Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.

Ajami NJ, Cope JL, Wong MC, Petrosino JF, Chesnel L.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02112-17. doi: 10.1128/AAC.02112-17. Print 2018 May.

5.

Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.

Warn P, Thommes P, Sattar A, Corbett D, Flattery A, Zhang Z, Black T, Hernandez LD, Therien AG.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6471-6482. doi: 10.1128/AAC.00974-16. Print 2016 Nov.

6.

Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis.

Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda C, Xavier J, Pamer EG.

Infect Immun. 2012 Jan;80(1):62-73. doi: 10.1128/IAI.05496-11. Epub 2011 Oct 17.

7.

Antibiotics involved in Clostridium difficile-associated disease increase colonization factor gene expression.

Denève C, Deloménie C, Barc MC, Collignon A, Janoir C.

J Med Microbiol. 2008 Jun;57(Pt 6):732-8. doi: 10.1099/jmm.0.47676-0.

PMID:
18480330
8.

Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficile.

Nagaro KJ, Phillips ST, Cheknis AK, Sambol SP, Zukowski WE, Johnson S, Gerding DN.

Antimicrob Agents Chemother. 2013 Nov;57(11):5266-70. doi: 10.1128/AAC.00580-13. Epub 2013 Aug 12.

9.

The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection.

Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB.

Gut Microbes. 2011 May-Jun;2(3):145-58. Epub 2011 May 1.

10.

Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters.

Fekety R, Silva J, Toshniwal R, Allo M, Armstrong J, Browne R, Ebright J, Rifkin G.

Rev Infect Dis. 1979 Mar-Apr;1(2):386-97.

PMID:
549190
11.

Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile.

Peterfreund GL, Vandivier LE, Sinha R, Marozsan AJ, Olson WC, Zhu J, Bushman FD.

PLoS One. 2012;7(10):e46966. doi: 10.1371/journal.pone.0046966. Epub 2012 Oct 10.

12.

Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones.

Phillips ST, Nagaro K, Sambol SP, Johnson S, Gerding DN.

Anaerobe. 2011 Aug;17(4):166-9. doi: 10.1016/j.anaerobe.2011.03.015. Epub 2011 Apr 14.

PMID:
21511046
13.

Clostridium difficile, the Difficult "Kloster" Fuelled by Antibiotics.

Dicks LMT, Mikkelsen LS, Brandsborg E, Marcotte H.

Curr Microbiol. 2019 Jun;76(6):774-782. doi: 10.1007/s00284-018-1543-8. Epub 2018 Aug 6. Review.

PMID:
30084095
14.

Fecal Microbiome Among Nursing Home Residents with Advanced Dementia and Clostridium difficile.

Araos R, Andreatos N, Ugalde J, Mitchell S, Mylonakis E, D'Agata EMC.

Dig Dis Sci. 2018 Jun;63(6):1525-1531. doi: 10.1007/s10620-018-5030-7. Epub 2018 Mar 28.

15.

Use your antibiotics wisely. Consequences to the intestinal microbiome.

Cervantes J.

FEMS Microbiol Lett. 2016 May;363(10). pii: fnw081. doi: 10.1093/femsle/fnw081. Epub 2016 Apr 3.

PMID:
27044298
16.

[Individualized treatment strategies for Clostridium difficile infections].

Solbach P, Dersch P, Bachmann O.

Internist (Berl). 2017 Jul;58(7):675-681. doi: 10.1007/s00108-017-0268-2. Review. German.

PMID:
28589214
17.

Effects of β-lactam antibiotics and fluoroquinolones on human gut microbiota in relation to Clostridium difficile associated diarrhea.

Knecht H, Neulinger SC, Heinsen FA, Knecht C, Schilhabel A, Schmitz RA, Zimmermann A, dos Santos VM, Ferrer M, Rosenstiel PC, Schreiber S, Friedrichs AK, Ott SJ.

PLoS One. 2014 Feb 28;9(2):e89417. doi: 10.1371/journal.pone.0089417. eCollection 2014.

18.

In vitro and in vivo activities of nitazoxanide against Clostridium difficile.

McVay CS, Rolfe RD.

Antimicrob Agents Chemother. 2000 Sep;44(9):2254-8.

19.

Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters.

Merrigan MM, Sambol SP, Johnson S, Gerding DN.

J Infect Dis. 2003 Dec 15;188(12):1922-7. Epub 2003 Dec 9.

PMID:
14673773
20.

Effect of a national 4C antibiotic stewardship intervention on the clinical and molecular epidemiology of Clostridium difficile infections in a region of Scotland: a non-linear time-series analysis.

Lawes T, Lopez-Lozano JM, Nebot CA, Macartney G, Subbarao-Sharma R, Wares KD, Sinclair C, Gould IM.

Lancet Infect Dis. 2017 Feb;17(2):194-206. doi: 10.1016/S1473-3099(16)30397-8. Epub 2016 Nov 4.

PMID:
27825595

Supplemental Content

Support Center